Gross profit (GAAP) was $339,000 for the six months ended June 30, 2025, down from $799,000 in 2024, yielding a gross margin of 28% versus 46% for the six months ended June 30 in 2025 and 2024, ...

Cowboys owner Jerry Jones revealed he quietly battled stage 4 melanoma for over a decade, crediting experimental ...

The study provides valuable technical advances to generate and isolate neural rosettes. The technique is robust, as indicated by both reviewers. The evidence is solid, as shown in orthogonal ...

Lipid nanoparticles without drugs can make some cancer cells swell and burst, offering a new way to target tumors resistant ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

With ongoing clinical trials and promising early data, tegoprubart may soon redefine the standard of care in transplantation ...

Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3 - Anticipated data ...

HOUSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates ...

Queuosine, supplied from food and our own gut bacteria, plays a vital role in human health. Researchers have just discovered ...

Key Points Net loss (GAAP) narrowed sharply to $33.9 million in Q2 2025, compared to $63.2 million in Q2 2024. Cash and investments (GAAP) totaled $386.7 million as of Q2 2025, and are projected to ...

Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor: Berlin, Germany Wednesday, August 13, 2025, 11:00 ...

We rushed her for scans, which confirmed a large mass in her lung and lesions in the brain. Fluid around her lungs was ...